Emcure expands Poviztra® use for MASH following CDSCO approval of GLP-1 agonist
Emcure Pharmaceuticals Ltd has announced that its co-marketed brand, Poviztra®, which contains innovator semaglutide (rDNA origin), will be available for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults. This expansion follows the Central Drugs Standard Control Organization's (CDSCO) approval of Wegovy® for the indication, significantly addressing a critical unmet medical need in treating this progressive liver disease.The availability of Poviztra® now allows Emcure and its subsidiaries to offer the new indication, expanding access to innovator semaglutide for patients suffering from MASH. This condition, which is closely linked with obesity and type 2 diabetes, occurs when excess fat accumulation leads to chronic inflammation, fibrosis, and progressive liver damage.
The approval makes the molecule from Novo Nordisk the first and only GLP-1 receptor agonist approved in India for the treatment of MASH. Poviztra® will be prescribed for adults presenting with moderate to advanced liver fibrosis (F2-F3).
Clinical Significance
The approval is supported by results from the global Phase III ESSENCE trial, which demonstrated semaglutide's potential to improve outcomes in affected patients. The study showed resolution of steatohepatitis in 63% of participants and an improvement in liver fibrosis in 37% of patients.Satish Mehta, Chief Executive Officer & Managing Director of Emcure Pharmaceuticals Limited, commented on the development: "The approval for MASH marks an important milestone for patients living with a serious and often underdiagnosed liver disease. We are pleased to make this important new indication available through Poviztra®, further strengthening our commitment to bringing globally validated, innovative therapies to patients in India."
Overview of Poviztra®
Poviztra® contains innovator semaglutide (rDNA-origin) and has an established role in chronic weight management. It is currently approved and marketed for individuals living with obesity and who are overweight with co-morbid conditions such as Hypertension, Dyslipidaemia, or Type 2 Diabetes. The drug is also used for the management of adolescent obesity in patients over 12 years old and for obese patients with established cardiovascular disease.The addition of the MASH indication enhances Emcure's commitment to addressing complex metabolic diseases through innovative therapies while supporting physicians in improving long-term patient outcomes.
About Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd (EPL) is a leading Indian pharma company based in Pune, dedicated to developing and globally marketing a broad range of pharmaceutical products. Established in 1981, EPL is an R&D driven company with a focus on innovation and quality. As of March 2026, EPL was ranked as the 13th largest pharma company in India regarding Domestic Sales. The company operates in over 70 countries worldwide, including Europe and Canada.EMCURE Stock Price Movement
Today, shares of Emcure Pharmaceuticals Limited edged higher to close at ₹1861.20, rallying 4.42% in post-market trading. The equity settled after a day strong enough to see a total traded volume of 195,372 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.